Introduction
In epidemiological terms, the incidence of prostate cancer (PCa) rises with age, but not in a linear fashion ( Table 1 ), suggesting that the incidence is almost one in 100 by the age of 75, with an associated mortality of about one in 400. With the data from the German Tumor Registry in Munich, we have been able to estimate that the present annual incidence rate in Germany is 36,000 cases per annum.
Screening programs represent an ef®cient way of monitoring a healthy population for the presence of a particular condition over a given period of time. On economic grounds, normally only the age groups judged most at risk of having or developing a given condition are examined. In screening programs for the detection of early PCa, patients with lower-urinary-tract symptoms (LUTS) have a higher prostate-speci®c antigen (PSA) level than men of the same age without LUTS.
Status of an earlier screening program in Germany
In Germany, a national early detection screening program for prostate cancer has been in operation for almost 30 y. When it was started in 1971, it was based on the general belief that establishing an early diagnosis of PCa would allow the urologist to treat the patient successfully by surgical means. The program was initiated largely due to the efforts of a very distinguished urologist, Professor CE Alken. In the German early detection program for men aged 45 y and older, a digital rectal examination (DRE) is performed and each participant answers a question concerning LUTS.
Unfortunately, the participation rate has never been more than 17%. Approximately 13 million men were screened annually. A total of 10,682 biopsies were performed on this large group, and PCa was detected in 1517 of them. This gives a case-®nding ratio of only 0.12%, suggesting a low overall effectiveness of the program. 2 This poor performance has become a political issue in Germany and is currently being debated. Under the in¯uence of the results of the European Randomized Study of Screening for Prostatic Carcinoma, which has a participation rate of 45%, and on the basis of ®ndings from DRE, PSA and transrectal ultrasonography (TRUS), a new study program was implemented. 3 Early detection study of the German Urological Association
Study design
In September 1997, 2400 urologists in Germany were asked to participate in the study. A total of 1200 urologists complied and received 20 forms consisting of two parts. Form 1 documents the men's medical history, performance score (Karnofsky) and ®ndings from DRE, TRUS (facultative), but not PSA levels. Form 2 contains results of a prostate biopsy, a bone scan, the eventual treatment, tumor node metastasis stage and Gleason score (facultative). Blood for the central PSA determination was drawn and mailed together with form 1 to the data center. Biopsies were recommended for participants with a pathologic DRE and a PSA b 4 ng/ml. Only men aged 45 ± 75 y could participate. 
Results
A total of 11,656 men took part in 963 participating centers, of which 814 were practice-based centers and 149 were clinical departments of urology, with a PSA level less than 4 ng/ml taken as the cut-off point. The distribution of PSA levels in this patient collective shows that the gray zone (PSA 4 ± 10 ng/ml) represents about 13%, and PSA b 10 ng/ml about 4% (Figure 1 ). In addition, the pattern of age distribution of PSA shows that, in contrast to the normal range of PSA level represented by the left column (PSA`4 ng/ml), there is a decline from nearly 100% in men aged 45 ± 49 y to about 70% in men in the 70 ± 75 y age group. There is a related increase in the gray columns (PSA 4-10 ng/ml) from around 2% in the 45-49 y age group to over 20% in the 70-75 y age group, and there is also a steady increase with age in the right columns (PSA b 10 ng/ml) ( Figure 2 ). Participating patients underwent a total of 1113 biopsies; ®ndings were normal in more than 57%. Benign prostatic hyperplasia was con®rmed in 7.7%, prostatitis in 11.3%, and 23.5% were found to have PCa ( Figure 3 ). As mentioned earlier, whereas the case-®nding ratio of the national screening program in Germany was only 0.12%, the corresponding ®gure for the present study is 2.2%, thus representing almost a 20-fold improvement. This provides good evidence to support the belief that the effectiveness of a PSA-based screening program is much higher than that involving DRE (done mostly by physicians not specializing in urology). Therefore, it should be remembered that only urologists took part in this study, and the vast majority of the participants would most likely have presented with LUTS. This could create a preselection bias.
An analysis of the ®ndings on the 262 PCa cases suggests that the incidence of prostate cancer was 55% in patients with a PSA level greater than 4 ng/ml, but with negative ®ndings from DRE. In patients with a PSA level less than 4 ng/ml and positive ®ndings from DRE, the ®gure was only 6% (Figure 4) . These data allow the positive predictive value (PPV) to be calculated. When the PSA level is greater than 4 ng/ml, negative DRE ®ndings lower the PPV to only 18%, while positive DRE ®ndings raise the PPV to 40%. Again, it is worthwhile noting that all the participating clinicians in this study were urologists, in contrast to the national program where general practitioners also took part and did their own DRE. Naturally, this is likely to have made a signi®cant difference. These data agree well with those from the United States. 4 More information can be obtained by stratifying the men's population according to age, which also suggests a gradual increase in the mean PSA level with age if cancer is present ( Figure 5 ). Looking at the median lines, one might ask why the 50th percentile is so low, but the wide distribution of PSA values from about 2 to 100 ng/ml accounts for the fact that the median, unlike the mean, is low. In 139 of 262 patients with PCa, the pathologic stage was determined. Among those who were DRE-negative, PCa with PSA 4 ± 10 ng/ml, 45 patients had stage pT2, and eight patients had stage pT4 cancer, however, when the PSA exceeded 10 ng/ml, 12 patients had stage pT2, but 16 patients had stage pT3 or stage pT4 cancer. Among the DRE-positive PCa, the case distribution (absolute numbers) in the PSA 0 ± 4 ng/ml range was 6 : 1 (stage pT2 : stage pT3, or stage pT4), 13 : 6 in the PSA range 4 ± 10 ng/ml, and 16 : 16 in the PSA category b 10.0 ng/ml.
Problems associated with PSA testing PSA testing has its problems, as illustrated by the receiveroperator characteristic analysis, where the x-axis gives the false-positive results (i.e. patients with a PSA level b 4 ng/ml, but no cancer), and the y-axis represents the sensitivity of the detection rate (Figure 6) . Ideally, the sensitivity should be 100, with a zero incidence of false positive results. If one looks at the total PSA levels with the Hybritech Tandem R method, the thick line represents the total PSA level, which is clearly somewhat distant from the ideal curve. If a sensitivity of 60% is obtained, the associated false-positive rate rises to over 70%. This is the problem that urologists encounter. Attempts have been made to improve results by determining the ratio of free total PSA in comparison with total PSA. Although this helps to move the curve slightly in the direction of the ideal curve, the situation is still far from satisfactory. Looking at the area under the curve (AUC), the total PSA is 61% and the free/total ratio is 70%, signifying very little improvement. Changing the centrally used Tandem R-assay to Elecsys did not alter the AUC (Figure 7 ). Even combining both assays did not alter the result (Figure 8) . A rise in sensitivity leads to an unacceptable level of falsepositive results, for example, by lowering the speci®city.
Summary
In a joint effort, urologists in Germany screened 11,656 men for carcinoma of the prostate using PSA levels, DRE Figure 5 Percentile for prostate-speci®c antigen (PSA) related to age in the study population and distribution of PSA in patients with carcinoma of the prostate. Figure 6 Total prostate-speci®c antigen (PSA) and the ratio of free/total PSA using the Hybritech Tandem R (preliminary data).
Figure 7
Total prostate-speci®c antigen (PSA) and the ratio of free/total PSA using the Elecsys (preliminary data).
®ndings and, eventually, ®ndings from TRUS and the patients' medical histories and Karnofsky scores. The PSA level was centrally determined. A total of 1113 patients underwent biopsies, and carcinoma of the prostate was found in 23.4%. This yields a case-®nding ratio almost 20-fold more than that obtained in the National Screening Program of Germany. Of the patients with cancer, 55% had a negative DRE result, but a PSA level greater than 4 ng/ml, and 5% had a positive DRE result, but a PSA level less than 4 ng/ml. A total of 139 of 262 patients with PCa underwent radical prostatectomy. Of the patients who were DRE-negative and had PSA levels in the gray zone, 42 had stage pT2 and eight had stage pT4 cancer, however, when the PSA level exceeded 10 ng/ml, 12 men had stage pT2, but 16 had stage pT3 or stage pT4 cancer. Among the patients who were DRE-positive and had cancer, the case distribution and absolute numbers in the PSA 0 ± 4 ng/ml range was 6 : 1 (stage pT2 : stage pT3 or stage pT4), in the PSA gray zone the range was 13:6, and in the PSA category b 10 ng/ml it was 16 : 16.
In this nationwide effort, a second early detection week took place in November 1998, and the detection rate was 20-fold higher with PSA testing than without, as is the case in the German National Screening Program. The problems encountered were the low sensitivity and speci®city of the PSA testing. Furthermore, in 47 of 139 pathologically staged tumors, the ideal indication for radical prostatectomy had not been met. However, these preliminary data re¯ect the joint efforts and serve as a basis for the ongoing discussion concerning the ef®cacy of national screening programs.
